CENTOGENE Genetic Testing

A multiomic test that combines custom whole exome sequencing (WES) with biochemical markers, enzyme assays, and a medical report; includes automated reflex analysis for specific findings.

Whole Genome Sequencing (WGS) within the MOx framework, combines genomic analysis with biochemical testing; provides more complete coverage of intronic and non-coding regions compared to WES.

A version of MOx that adds RNA (transcriptomic) analysis to WES and biochemical testing, enhancing the detection of splicing and regulatory variants.

WGS combined with biochemical markers and RNA analysis (MOx 2.0) for a highly detailed multiomic approach.

Combines genetic analysis and biochemical testing for the diagnosis of inborn metabolic disorders (IMD).

Whole Exome Sequencing (WES) for a single patient (Solo).

Whole Genome Sequencing (WGS) for a single patient (Solo), a comprehensive genomic analysis for full diagnostic insight.

Prenatal/reproductive screening using genomic methods to assess risk and detect variants associated with inherited disorders.

Microarray (array-based) analysis for CNVs, enabling high-resolution detection of deletions and duplications.

This panel/test is designed for the diagnosis of the clinical condition specified in the title. It typically includes a selected set of genes known to be associated with the specific disease or syndrome and uses NGS (panel-based sequencing) or other molecular methods (MLPA, Sanger, qPCR) for detecting certain variants.

This panel is focused on diagnosing amyotrophic lateral sclerosis (ALS) and dementia-related disorders. It typically includes a selected set of genes known to be associated with these conditions, analyzed using NGS (panel-based sequencing) or specific molecular methods (MLPA, Sanger sequencing, qPCR) for certain variants.

This panel is focused on the diagnosis of ataxia and hereditary spastic paraplegia. It typically includes a selected set of genes known to be associated with these conditions, analyzed via NGS (panel-based sequencing) or specific molecular methods (MLPA, Sanger sequencing, qPCR) for certain variants.

This panel is designed to diagnose the clinical conditions stated in the title. It typically includes a carefully selected set of genes known to be associated with ataxia and hereditary spastic paraplegia, analyzed via NGS (panel-based sequencing) or specific molecular methods (MLPA, Sanger sequencing, qPCR) for certain variants.

This panel is designed to diagnose conditions associated with repeat expansion disorders that lead to ataxia. It typically includes a selected set of genes known to be implicated in such disorders and is analyzed using NGS (panel-based sequencing) or specific molecular methods (MLPA, Sanger sequencing, qPCR) for certain variants.

This panel is designed for the diagnosis of atypical hemolytic uremic syndrome (aHUS). It typically includes a selected set of genes known to be associated with the condition and is analyzed using NGS (panel-based sequencing) or specific molecular methods (MLPA, Sanger sequencing, qPCR) for particular variants.

This panel is designed for the diagnosis of coagulopathies. It typically includes a selected set of genes known to be associated with blood clotting disorders and is analyzed using NGS (panel-based sequencing) or specific molecular methods (MLPA, Sanger sequencing, qPCR) for certain variants.

This panel is designed for the diagnosis of bone marrow failure syndromes and genetic forms of anemia. It typically includes a selected set of genes known to be associated with these conditions, analyzed using NGS (panel-based sequencing) or specific molecular methods (MLPA, Sanger sequencing, qPCR) for certain variants.

This panel is designed to diagnose hereditary breast and ovarian cancer syndromes associated with BRCA1 and BRCA2 gene mutations. It typically includes sequencing and analysis of these key genes using NGS (panel-based sequencing) or specific molecular methods (MLPA, Sanger sequencing, qPCR) for certain variants.

This panel is designed to diagnose hereditary breast, ovarian, and related cancers by analyzing BRCA1 and BRCA2, along with additional genes associated with these conditions. It uses NGS (panel-based sequencing) or specific molecular methods (MLPA, Sanger sequencing, qPCR) for selected variants.

This panel is designed to detect somatic mutations in BRCA1 and BRCA2 genes, commonly associated with tumor profiling and targeted cancer therapies. It typically involves sequencing of selected genes using NGS (panel-based sequencing) or specific molecular methods (MLPA, Sanger sequencing, qPCR) for detecting certain variant types.

This panel is designed for the diagnosis of hereditary breast cancer and related syndromes. It includes a selected set of genes known to be associated with these conditions and is analyzed using NGS (panel-based sequencing) or specific molecular methods (MLPA, Sanger sequencing, qPCR) for particular variants.

This panel is designed for the diagnosis of hereditary cancer syndromes. It includes a selected set of genes known to be associated with increased cancer risk, analyzed using NGS (panel-based sequencing) or specific molecular methods (MLPA, Sanger sequencing, qPCR) for certain variant types.

This panel is designed for the diagnosis of hereditary cancer syndromes. It includes an expanded set of genes known to be associated with increased cancer risk and is analyzed using NGS (panel-based sequencing) or specific molecular methods (MLPA, Sanger sequencing, qPCR) for select genetic variants.

This panel is designed for the diagnosis of hereditary pediatric cancers. It includes a selected set of genes known to be associated with childhood-onset cancer syndromes and is analyzed using NGS (panel-based sequencing) or specific molecular methods (MLPA, Sanger sequencing, qPCR) for particular variants.

This panel is designed to assess genetic predisposition to cancer by analyzing key genes associated with increased cancer risk. Testing is performed using NGS (panel-based sequencing) or specific molecular methods (MLPA, Sanger sequencing, qPCR) for select variant types.

This panel is designed for the diagnosis of hereditary cardiovascular disorders. It includes a selected set of genes known to be associated with conditions such as cardiomyopathies, arrhythmias, and vascular disorders. Testing is performed using NGS (panel-based sequencing) or specific molecular methods (MLPA, Sanger sequencing, qPCR) for certain variant types.

This panel is designed for the diagnosis of genetic syndromes associated with dysmorphic features and developmental anomalies. It includes a selected set of genes known to be linked to such conditions and is analyzed using NGS (panel-based sequencing) or specific molecular methods (MLPA, Sanger sequencing, qPCR) for particular variant types.

This panel is designed for the diagnosis of hereditary hearing loss and related otological disorders. It includes a selected set of genes known to be associated with syndromic and non-syndromic forms of hearing impairment, analyzed using NGS (panel-based sequencing) or specific molecular methods (MLPA, Sanger sequencing, qPCR) for select variant types.

This panel is designed for rapid and targeted genetic diagnosis in critical care settings, including neonatal and pediatric intensive care units. It includes a selected set of genes associated with life-threatening genetic conditions and syndromes, analyzed using NGS (panel-based sequencing) or specific molecular methods (MLPA, Sanger sequencing, qPCR) for certain variant types.

This panel is designed for the diagnosis of inborn errors of metabolism (IEM). It includes a selected set of genes known to be associated with metabolic disorders and is analyzed using NGS (panel-based sequencing) or specific molecular methods (MLPA, Sanger sequencing, qPCR) for certain variant types.

This panel/test is designed for the diagnosis of disorders within the clinical area indicated in the title. It typically includes a curated set of genes known to be associated with specific immunological diseases or syndromes. Analysis is performed using NGS (panel-based sequencing) or specialized molecular methods such as MLPA, Sanger sequencing, or qPCR for select variant types.

This panel/test is designed to diagnose disorders related to the clinical area specified in the title, focusing on mitochondrial diseases. It typically includes a curated selection of genes known to be associated with mitochondrial dysfunction and related syndromes. Analysis is performed using NGS (targeted panel sequencing) or specialized molecular techniques such as MLPA, Sanger sequencing, or qPCR for certain variant types.

This panel/test is designed for the diagnosis of mitochondrial disorders, as specified in the title. It typically includes a selected set of genes known to be associated with mitochondrial diseases or related syndromes. Testing is performed using Next-Generation Sequencing (NGS) panels or specialized molecular methods such as MLPA, Sanger sequencing, or qPCR for specific variant types.

This panel/test is designed to diagnose the clinical condition specified in the title. It typically includes a selected set of genes known to be associated with the relevant disease or syndrome. Testing is performed via Next-Generation Sequencing (NGS) panels or specialized molecular methods such as MLPA, Sanger sequencing, or qPCR for specific variants.

This panel/test is intended for the diagnosis of the clinical condition specified in the title. It typically includes a selected set of genes known to be associated with the relevant disease or syndrome. Testing is performed using Next-Generation Sequencing (NGS) panels or specialized molecular methods such as MLPA, Sanger sequencing, or qPCR for specific variant types.

This panel/test is intended for the diagnosis of the clinical condition specified in the title. It typically includes a selected set of genes known to be associated with the specific disease or syndrome, using Next-Generation Sequencing (NGS) panels or specialized molecular methods such as MLPA, Sanger sequencing, or qPCR for certain variants.

This panel/test is intended for the diagnosis of the clinical condition specified in the title. It typically includes a selected set of genes known to be associated with the specific disease or syndrome, using Next-Generation Sequencing (NGS) panels or specialized molecular methods such as MLPA, Sanger sequencing, or qPCR for certain variants.

This panel/test is designed for the diagnosis of the clinical condition specified in the title. It typically includes a selected set of genes known to be associated with the specific disease or syndrome, analyzed using Next-Generation Sequencing (NGS) panels or specialized molecular methods such as MLPA, Sanger sequencing, or qPCR for certain variants.

This panel/test is designed for the diagnosis of congenital adrenal hyperplasia (CAH). It typically includes a selected set of genes known to be associated with this condition, analyzed using Next-Generation Sequencing (NGS) panels or specialized molecular methods such as MLPA, Sanger sequencing, or qPCR for certain variants.

This panel/test is designed for the diagnosis of the clinical condition described in the title. It typically includes a selected set of genes known to be associated with specific connective tissue disorders, analyzed using Next-Generation Sequencing (NGS) panels or specialized molecular methods such as MLPA, Sanger sequencing, or qPCR for certain variants.

This panel/test is designed to diagnose the clinical conditions associated with diabetes and obesity. It typically includes a selected set of genes known to be related to these disorders, analyzed using Next-Generation Sequencing (NGS) panels or specialized molecular methods such as MLPA, Sanger sequencing, or qPCR for specific variants.

This panel/test is designed for the diagnosis of epilepsy and related neurological disorders. It typically includes a selected set of genes known to be associated with epilepsy, analyzed using Next-Generation Sequencing (NGS) panels or specialized molecular methods such as MLPA, Sanger sequencing, or qPCR for specific variant types.

This panel/test is designed for the diagnosis of intellectual disability and related neurodevelopmental disorders. It typically includes a selected set of genes known to be associated with these conditions, analyzed using Next-Generation Sequencing (NGS) panels or specialized molecular methods such as MLPA, Sanger sequencing, or qPCR for specific variants.

This panel/test is designed for the diagnosis of myeloid tumors and related hematologic disorders. It typically includes a selected set of genes known to be associated with these conditions, analyzed using Next-Generation Sequencing (NGS) panels or specialized molecular techniques such as MLPA, Sanger sequencing, or qPCR for specific variants.

This panel/test is designed for the diagnosis of neuromuscular disorders. It typically includes a selected set of genes known to be associated with the relevant diseases or syndromes, analyzed using Next-Generation Sequencing (NGS) panels or specific molecular methods such as MLPA, Sanger sequencing, or qPCR for certain variants.

This panel/test is aimed at diagnosing the clinical condition indicated in the title. It typically includes a selected set of genes known to be associated with

This panel/test is intended for diagnosing the clinical condition stated in the title. It typically includes a selected set of genes known to be associated with

This panel/test is designed for diagnosing disorders related to the

This panel/test is designed for the diagnosis of disorders associated with